KBC Group
TVTX icon

KBC Group’s Travere Therapeutics TVTX Stock Holding History

KBC Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Hold
2,843
– – ﹤0.01% 1129
2026
Q1 		$84K Sell
2,843
-1,344
-32% -$40.2K ﹤0.01% 1426
2025
Q4 		$160K Hold
4,187
– – ﹤0.01% 1004
2025
Q3 		$100K Hold
4,187
– – ﹤0.01% 1263
2025
Q2 		$62K Hold
4,187
– – ﹤0.01% 1488
2025
Q1 		$75K Buy
+4,187
New +$85K ﹤0.01% 1639

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's TVTX Position: Q2 2026 in Review

KBC Group held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 2,843 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #1129.

KBC Group first reported a position in TVTX in Q1 2025 and has held it in 6 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • KBC Group held 2,843 shares of Travere Therapeutics worth $162K as of Q2 2026.
  • KBC Group left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1129 holding.
  • KBC Group first reported a position in Travere Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.